In the last trading session, 1.26 million shares of the ARS Pharmaceuticals Inc (NASDAQ:SPRY) were traded, and its beta was 0.78. Most recently the company’s share price was $14.99, and it changed around $0.52 or 3.59% from the last close, which brings the market valuation of the company to $1.47B. SPRY currently trades at a discount to its 52-week high of $18.51, offering almost -23.48% off that amount. The share price’s 52-week low was $7.55, which indicates that the current value has risen by an impressive 49.63% since then. We note from ARS Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 2.1 million shares, with the 3-month average coming to 1.69 million.
ARS Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended SPRY as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. ARS Pharmaceuticals Inc is expected to report earnings per share of -0.36 for the current quarter.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY has showed a green trend with a performance of 3.59% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 15.00 on recent trading dayincreased the stock’s daily price by 0.07%. The company’s shares are currently up 42.09% year-to-date, but still up 21.57% over the last five days. On the other hand, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 31.03% up in the 30-day period. We can see from the shorts that 17.15 million shares have been sold at a short interest cover period of 8.66 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 31.86% from its current value. Analyst projections state that SPRY is forecast to be at a low of $18 and a high of $30.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
The year-over-year growth rate is expected to be -6.80%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 7.48M in revenue for the current quarter. 6 analysts expect ARS Pharmaceuticals Inc to make 14.71M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 2,842.30%.
ARS Pharmaceuticals Inc earnings are expected to increase by -1764.10% in 2025, but the outlook is positive 43.97% per year for the next five years.
SPRY Dividends
ARS Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-19.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 22.97% of ARS Pharmaceuticals Inc shares, and 74.91% of them are in the hands of institutional investors. The stock currently has a share float of 97.26%. ARS Pharmaceuticals Inc stock is held by 231.0 institutions, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) being the largest institutional investor. By 2024-06-30, it held 11.4409% of the shares, which is about 11.08 million shares worth $94.27 million.
RA CAPITAL MANAGEMENT, L.P., with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 1.99 shares worth $29.85 million, making up 2.03% of all outstanding shares. On the other hand, SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF held roughly 1.49 shares worth around $22.35 million, which represents about 1.52% of the total shares outstanding.
